Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against AdaptHealth Corp.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is AdaptHealth Corp. (AHCO) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AdaptHealth Corp. (“AdaptHealth” or “the Company”) (NASDAQ: AHCO). Investors who purchased AdaptHealth securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether AdaptHealth has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On August 5, 2026, AdaptHealth Corp. shares fell as much as 26% after the Company reported second-quarter revenue of $740.3 million, well below the approximately $847 million expected, a GAAP loss driven in part by a $144.2 million goodwill impairment charge, and a substantial reduction to full-year guidance. Adjusted EBITDA came in at $132 million for the quarter, against roughly $160 million expected. Alongside those results, AdaptHealth reset its 2026 continuing-operations outlook to approximately $2.85 billion to $2.89 billion in revenue and $490 million to $520 million in adjusted EBITDA — a decline of roughly 16% to 19% from the guidance figures the Company had carried just weeks earlier. Management attributed the reset to the Diabetes Health divestiture, a capitated contract, manufacturer pricing, and other portfolio actions.
What Should AdaptHealth Corp. (AHCO) Investors Do?
If you are aware of any facts relating to this investigation or purchased AdaptHealth securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did AdaptHealth Corp. (AHCO) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”